Asset
Trastuzumab Pamirtecan
BioNTech SE American Depositary Share
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06340568 | phase3 | recruiting | 2025-06-10 | 2028-03-01 | BioNTech SE | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer |
FDA applications (0)
This company has no applications containing this asset.